Supporting this, in a phase 2a trial in people with MASLD, the dual GLP-1/GCG agonist efinopegdutide (10 mg) reduced liver fat by 72.7%, compared to 42.3% with semaglutide (1 mg) despite similar WL—indicating potential weight-independent effects of GCG on hepatic steatosis [40]. The gene discussed is GCG; the disease is fatty liver disease.